Related Experiment Video
Updated: May 19, 2026

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
Dynamic vascular changes following intravenous antibiotics in patients with cystic fibrosis
James H Hull1, Rachel Garrod2, Timothy B Ho3
1Centre for Clinical Pharmacology, Division of Biomedical Sciences, St George's, University of London, Cranmer Terrace, London. SW17 0RE, UK.
Background:
Adults with cystic fibrosis (CF) have altered large artery haemodynamics which is associated with a persisting systemic inflammatory state. We hypothesized that a short-term intervention favorably influencing the inflammatory status may modify their haemodynamic state.
Methods:
Adult patients with CF were studied immediately preceding and following 2 weeks of intravenous antibiotics. Large artery haemodynamics, principally heart rate-adjusted augmentation index (AIx) were obtained. Blood pressure (BP), spirometry and CRP were also measured.
Results:
Complete data was available for 15 patients; mean (SD) age 28 (6)years. CRP was reduced while FEV1% predicted improved. Following treatment AIx was lower: 10.9 (10.9)% to 8.1 (10.9)% (p<0.05) while BP was similar and a trend toward lower heart rate (p=0.06). Change in AIx was related to baseline FEV1% predicted (r=0.77) and BMI (r=0.71) (both P<0.01).
Conclusion:
The abnormal central haemodynamics evident in adults with CF is modulated with a short intervention of intravenous antibiotics.
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Aneurysm IV: Nursing Management
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

